Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus chemotherapy vs rituximab plus chemotherapy in previously untreated advanced indolent non-Hodgkin's lymphoma
jRCT2080221619Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab and rituximab in mature B-cell lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Oct 2011; status: completed.
02
Drugs
obinutuzumabrituximab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2080221619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221619.